Physicians' Academy for Cardiovascular Education
Reduction of CV and renal outcomes by empagliflozin in HFrEF patients in the EMPEROR-Reduced trial was independent of baseline NT-proBNP levels. Empagliflozin reduced NT-proBNP levels, which was associated with a reduction in adverse outcomes.
In this series, three experts in heart failure discuss the dilemma of discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia. Moreover, the option of novel potassium binders is presented, when and how to use these agents?
Prof. Coats discusses the dilemma when hyperkalemia occurs in HF patients: discontinuation/reducing RAASi and lose the benefits of RAASi vs. continued RAASi and accept the presence of hyperkalemia.
Hyperkalemia is a major clinical problem. Prof. Stefan Anker talks about problems and risk associated with hyperkalemia.
In SwedeHF, a nationwide HF registry in Sweden, approximately 1 in 4 patients with HF were tested for iron deficiency (ID). ID was present in half of the tested population. 1 in 5 patients with ID received ferric carboxymaltose.
The FDA has granted Breakthrough Therapy Designation to empagliflozin as an investigational treatment for patients with HFpEF, following the results from the EMPEROR-Preserved trial.
Empagliflozin significantly reduced epicardial adipose tissue, subcutaneous adipose tissue, myocardial extracellular volume, matrix volume, cardiomyocyte volume, aortic stiffness and several inflammatory biomarkers, compared to placebo in nondiabetic patients with HFrEF.
ESC 2021 After prof. Ruschitzka summarizes the EMPEROR-Preserved trial, he calls on us to reconsider our vision on dichotimizing HF by a threshold of EF.
ESC 2021 In the EMPEROR-Pooled analysis, the efffect of empagliflozin on kidney and HF outcomes was assessed across the full spectrum of ejection fraction in HF. Prof. De Boer talks about the exciting findings.
ESC 2021 Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.
ESC 2021 Data of two large trials with empagliflozin in patients with heart failure, EMPEROR-Reduced and EMPEROR-Preserved, were pooled for analysis. Milton Packer shares the findings of EMPEROR-Pooled.
ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.
